Clinical trialNo phase (not a drug trial)Not yet recruiting
MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- No phase (not a drug trial)
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 1 October 2025
- Expected end
- 30 June 2030
- Enrollment
- 30 participants
- Sites
- 0
- Primary outcomes
- Overall Survival
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 27 August 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The goal of this clinical trial is to learn if the use of dose-escalated MRI-guided irradiation increases the rates of disease control in patients with pancreatic cancer
Detailed description public domain (ClinicalTrials.gov)
The implementation of Magnetic Resonance Image Guided Radiotherapy (MRgRT) into a Pancreatic Cancer Intensification Program maximizes treatment objectives rates due to the better visualization and online dose-adaptation pancreatic tumor. Rationale In the radiation setting, MRI provides superior soft tissue contrast compared to standard onboard X-ray imaging improving inter- and intra- observer delineation variation. MRgRT offers the opportunity to adapt the plan at each fraction to the anatomical changes seen (Henke et al., 2018). This creates a much better CTV to OAR ratio in a 50Gy/5Rx scenario. Primary Objectives A. To achieve a 1-year survival of 85%. B. To decrease grade 4-5 gastrointestinal events to less than 5%. Secondary Objectives A. Determination of blood and urine biomarkers of treatment response and toxicity . B. Determination of radiomics biomarkers of treatment response and toxicity . C. Determination of quality of life with the EORTC QLQ-C30 Questionnaire .